<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>POLYMYXIN B- polymyxin b sulfateÂ injection, powder, lyophilized, for solutionÂ </strong><br>X-GEN Pharmaceuticals, Inc.<br></p></div>
<h1>POLYMYXIN B FOR INJECTION, USP<br><span class="Bold">For Parenteral and Opthalmic Administration</span>
</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="LINK_b0211179-9a93-4389-9f94-6191aaf3ab1a"></a><a name="section-1"></a><p></p>
<h1></h1>
<p class="First">To reduce the development of drug-resistant bacteria and maintain the effectiveness of Polymyxin and other antibacterial drugs, Polymyxin B for Injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by bacteria.</p>
</div>
<div class="Warning">
<a name="LINK_759b2721-514b-4dfa-961c-fab18f568514"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">WARNINGS </span></h1>
<p class="First">CAUTION: WHEN THIS DRUG IS GIVEN INTRAMUSCULARLY, INTRAVENOUSLY AND/OR INTRATHECALLY, IT SHOULD BE GIVEN ONLY TO HOSPITALIZED PATIENTS, SO AS TO PROVIDE CONSTANT SUPERVISION BY A PHYSICIAN.</p>
<p>RENAL FUNCTION SHOULD BE CAREFULLY DETERMINED AND PATIENTS WITH RENAL DAMAGE AND NITROGEN RETENTION SHOULD HAVE REDUCED DOSAGE. PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span> DUE TO POLYMYXIN B SULFATE USUALLY SHOW <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">ALBUMINURIA</span>, CELLULAR CASTS, AND <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">AZOTEMIA</span>. DIMINISHING URINE OUTPUT AND A RISING BUN ARE INDICATIONS FOR DISCONTINUING THERAPY WITH THIS DRUG.</p>
<p>NEUROTOXIC REACTIONS MAY BE MANIFESTED BY <span class="product-label-link" type="condition" conceptid="4184149" conceptname="Feeling irritable">IRRITABILITY</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">WEAKNESS</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">DROWSINESS</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ATAXIA</span>, PERIORAL <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">PARESTHESIA</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">NUMBNESS</span> OF THE EXTREMITIES, AND <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">BLURRING OF VISION</span>. THESE ARE USUALLY ASSOCIATED WITH HIGH SERUM LEVELS FOUND IN PATIENTS WITH <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">IMPAIRED RENAL FUNCTION</span> AND/OR <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">NEPHROTOXICITY</span>.</p>
<p>THE CONCURRENT OR SEQUENTIAL USE OF OTHER NEUROTOXIC AND/OR NEPHROTOXIC DRUGS WITH POLYMYXIN B SULFATE, PARTICULARLY BACITRACIN, STREPTOMYCIN, NEOMYCIN, KANAMYCIN, GENTAMICIN, TOBRAMYCIN, AMIKACIN, CEPHALORIDINE, PAROMOMYCIN, VIOMYCIN, AND COLISTIN SHOULD BE AVOIDED.</p>
<p>THE <span class="product-label-link" type="condition" conceptid="4024301" conceptname="Neurotoxicity">NEUROTOXICITY</span> OF POLYMYXIN B SULFATE CAN RESULT IN <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">RESPIRATORY PARALYSIS</span> FROM <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">NEUROMUSCULAR BLOCKADE</span>, ESPECIALLY WHEN THE DRUG IS GIVEN SOON AFTER ANESTHESIA AND/OR MUSCLE RELAXANTS.</p>
<p>USAGE IN PREGNANCY: THE SAFETY OF THIS DRUG IN HUMAN PREGNANCY HAS NOT BEEN ESTABLISHED.</p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="LINK_ddce8457-cdef-46f1-b488-01699ea80349"></a><a name="section-2"></a><p></p>
<h1><span class="Bold">DESCRIPTION </span></h1>
<p class="First">Polymyxin B Sulfate is one of a group of basic polypeptide antibiotics derived from<span class="Italics"> B polymyxa (B aerosporous)</span>. Polymyxin B sulfate is the sulfate salt of Polymyxins B1Â and B2, which are produced by the growth of <span class="Italics">Bacillus polymyxa</span> (Prazmowski) Migula (Fam. Bacillacea). It has a potency of not less than 6000 polymyxin B units per mg, calculated on the anhydrous basis. The structural formulae are:</p>
<div class="Figure">
<img alt="structure" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=805caef0-89df-4bcf-876d-9f6b7a89c9a3&amp;name=polymyxin-b-for-injection---usp-1.jpg"><p class="MultiMediaCaption">structure</p>
</div>
<p>Polymyxin B <span class="Sub">1</span> (R=CH <span class="Sub">3</span>)â€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒâ€ƒPolymyxin B <span class="Sub">2</span> (R=H)</p>
<p>Each vial contains 500,000 polymyxin B units for parenteral or ophthalmic administration.</p>
<p>Polymyxin B for Injection is in powder form suitable for preparation of sterile solutions for intramuscular, intravenous drip, intrathecal, or ophthalmic use.</p>
<p>In the medical literature, dosages have frequently been given in terms of equivalent weights of pure polymyxin B base. Each milligram of pure polymyxin B base is equivalent to 10,000 units of polymyxin B and each microgram of pure polymyxin B base is equivalent to 10 units of polymyxin B.</p>
<p>Aqueous solutions of polymyxin B sulfate may be stored up to 12 months without significant loss of potency if kept under refrigeration. In the interest of safety, solutions for parenteral use should be stored under refrigeration and any unused portion should be discarded after 72 hours. Polymyxin B sulfate should not be stored in alkaline solutions since they are less stable.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="LINK_a473ab09-92f0-4a51-a934-45e9ff8e36b7"></a><a name="section-3"></a><p></p>
<h1><span class="Bold">CLINICAL PHARMACOLOGY </span></h1>
<p class="First">Polymyxin B sulfate has a bactericidal action against almost all gram-negative bacilli except the <span class="Italics">Proteus</span> group. Polymyxins increase the permeability of bacterial cell wall membranes. All gram-positive bacteria, fungi, and the gram-negative cocci,<span class="Italics"> N gonorrhoeae</span> and <span class="Italics">N meningitidis</span>, are resistant. </p>
<p>Polymyxin B has bactericidal action against almost all Gram-negative bacilli except the <span class="Italics">Proteus</span> group. Polymyxins increase the permeability of the bacterial cell membrane leading to <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">death</span> of the cell. All Gram-positive bacteria, fungi, and Gram-negative cocci, are resistant to polymyxin B. Appropriate methods should be used when performing <span class="Italics">in vitro</span> susceptibility testing of polymyxin B (1,2,3). The following <span class="Italics">in vitro</span> susceptibility test criteria should only be used for interpreting the results of polymyxin B susceptibility testing against <span class="Italics">P. aeruginosa</span> when the indicated quality control parameters are met during testing. </p>
<table>
<col>
<col>
<col>
<col>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="7">Â In vitro susceptibility test interpretive criteria for <br>polymyxin B sulfate against Pseudomonas aeruginosa</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â </td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">Â Minimal Inhibitory Concentration<br>(MIC) (mcg/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">Â Disk Diffusion Interpretive<br>Criteria (mm) (300 unit disk)</td>
</tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Pathogen</td>
<td class="Botrule Lrule Toprule" align="center">SusceptibleÂ </td>
<td class="Botrule Toprule" align="center">IntermediateÂ </td>
<td class="Botrule Rrule Toprule" align="center">ResistantÂ </td>
<td class="Botrule Lrule Toprule" align="center">SusceptibleÂ </td>
<td class="Botrule Toprule" align="center">IntermediateÂ </td>
<td class="Botrule Rrule Toprule" align="center">ResistantÂ </td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Italics">Pseudomonas aeruginosa</span>
</td>
<td class="Botrule Lrule Toprule" align="center">Â â‰¤2</td>
<td class="Botrule Toprule" align="center">Â 4</td>
<td class="Botrule Rrule Toprule" align="center">Â â‰¥8</td>
<td class="Botrule Lrule Toprule" align="center">Â â‰¥12</td>
<td class="Botrule Toprule" align="center">Â -</td>
<td class="Botrule Rrule Toprule" align="center">Â â‰¤11</td>
</tr>
</tbody>
</table>
<table>
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First"><td class="Botrule Lrule Rrule Toprule" align="center" colspan="3">Â In vitro susceptibility test quality control ranges for polymyxin B sulfate against<br><span class="Italics">Pseudomonas aeruginosa</span>
</td></tr>
<tr>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Quality Control Organism<br>(ATCC* Number)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â Minimum Inhibatory ConcentrationÂ (MIC) Range (mcg/mL)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">
<p class="First">Â Disk Diffusion </p>
<p>Quality Control Range (300 unit disk) (mm)</p>
</td>
</tr>
<tr class="Last">
<td class="Botrule Lrule Rrule Toprule" align="center">Â <span class="Italics">Pseudomonas aeruginosa</span>Â Â Â Â Â Â  Â <br>(27853)</td>
<td class="Botrule Lrule Rrule Toprule" align="center">Â 1Â  - Â 4</td>
<td class="Botrule Lrule Rrule Toprule" align="center">14Â  -Â  18Â </td>
</tr>
</tbody>
</table>
<p>Polymyxin B sulfate is not absorbed from the normal alimentary tract. Since the drug loses 50 percent of its activity in the presence of serum, active blood levels are low. Repeated injections may give a cumulative effect. Levels tend to be higher in infants and children. The drug is excreted slowly by the kidneys. Tissue diffusion is poor and the drug does not pass the blood brain barrier into the cerebrospinal fluid. In therapeutic dosage, polymyxin B sulfate causes some <span class="product-label-link" type="condition" conceptid="4126119" conceptname="Toxic nephropathy">nephrotoxicity</span> with tubule damage to a slight degree.</p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="LINK_e1a31188-bfcb-4f17-a1c5-6d110496f532"></a><a name="section-4"></a><p></p>
<h1><span class="Bold">INDICATIONS AND USAGE </span></h1>
<p class="First"><span class="Italics">Acute <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">Infections</span> Caused by Susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">Strains</span> of Pseudomonas aeruginosa. </span></p>
<p>Polymyxin B sulfate is a drug of choice in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the urinary tract, meninges, and bloodstream caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Ps</span>. <span class="Italics">aeruginosa</span>. It may also be used topically and subconjunctivally in the treatment of <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of <span class="Italics">Ps</span>. <span class="Italics">aeruginosa</span>. </p>
<p>It may be indicated in serious <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> caused by susceptible <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of the following organisms, when less potentially toxic drugs are ineffective or contraindicated:</p>
<p><span class="Italics">H influenzae</span>, specifically meningeal <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.</p>
<p><span class="Italics">Escherichia</span>Â <span class="Italics">coli</span>, specifically <span class="product-label-link" type="condition" conceptid="81902" conceptname="Urinary tract infectious disease">urinary tract infections</span>.</p>
<p><span class="Italics">AerobacterÂ aerogenes</span>, specifically <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.</p>
<p><span class="Italics">Klebsiella</span>Â <span class="Italics">pneumoniae</span>, specifically <span class="product-label-link" type="condition" conceptid="132736" conceptname="Bacteremia">bacteremia</span>.</p>
<p>NOTE: IN MENINGEAL <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">INFECTIONS</span>, POLYMYXIN B SULFATE SHOULD BE ADMINISTERED <span class="Italics">ONLY</span> BY THE <span class="Italics">INTRATHECAL</span> ROUTE.</p>
<p>To reduce the development of drug-resistant bacteria and maintain the effectiveness of Polymyxin B for Injection USP and other antibacterial drugs, Polymyxin B for Injection should be used only to treat or prevent <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="LINK_5aa9b965-5324-4137-8a44-889d98263aec"></a><a name="section-5"></a><p></p>
<h1><span class="Bold">CONTRAINDICATIONS </span></h1>
<p class="First">This drug is contraindicated in persons with a prior history of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity reactions</span> to polymyxins. </p>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="LINK_19380cb0-d222-4248-aa19-073b647a5307"></a><a name="section-6"></a><p></p>
<h1><span class="Bold">WARNINGS</span></h1>
<p class="First">Clostridium difficile associated <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> (CDAD) has been reported with use of nearly all antibacterial agents, including Polymyxin B for Injection, and may range in severity from mild <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> to fatal <span class="product-label-link" type="condition" conceptid="4272488" conceptname="Colitis">colitis</span>. Treatment with antibacterial agents alters the normal flora of the colon leading to overgrowth of C. difficile. </p>
<p>C. difficile produces toxins A and B which contribute to the development of CDAD. Hypertoxin producing <span class="product-label-link" type="condition" conceptid="4168796" conceptname="Muscle strain">strains</span> of C. difficile cause increased morbidity and mortality, as these <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> can be refractory to antimicrobial therapy and may require colectomy. CDAD must be considered in all patients who present with <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span> following antibiotic use. Careful medical history is necessary since CDAD has been reported to occur over two months after the administration of antibacterial agents. </p>
<p>If CDAD is suspected or confirmed, ongoing antibiotic use not directed against C. difficile may need to be discontinued. Appropriate fluid and electrolyte management, protein supplementation, antibiotic treatment of C. difficile and surgical evaluation should be instituted as clinically indicated. </p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="LINK_3104aa64-38d6-48a7-ac5b-a0ced9a06861"></a><a name="section-7"></a><p></p>
<h1><span class="Bold">PRECAUTIONS </span></h1>
<p class="First"><span class="Bold">General.</span></p>
<p>Prescribing Polymyxin B for Injection in the absence of a proven or strongly suspected <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span> or a <span class="product-label-link" type="condition" conceptid="4118659" conceptname="Prophylactic">prophylactic</span> indication is unlikely to provide benefit to the patient and increase the risk of the development of drug-resistant bacteria.</p>
<p>See <span class="Bold">WARNING</span> box.</p>
<p>Baseline renal function should be done prior to therapy, with frequent monitoring of renal function and blood levels of the drug during parenteral therapy.</p>
<p>Avoid concurrent use of a curariform muscle relaxant and other neurotoxic drugs (ether, tubocurarine, succinylcholine, gallamine, decamethonium and sodium citrate) which may precipitate <span class="product-label-link" type="condition" conceptid="4214898" conceptname="Decreased respiratory function">respiratory depression</span>. If signs of <span class="product-label-link" type="condition" conceptid="4275136" conceptname="Paralysis of diaphragm">respiratory paralysis</span> appear, respiration should be assisted as required, and the drug discontinued. </p>
<p>As with other antibiotics, use of this drug may result in overgrowth of nonsusceptible organisms, including fungi.</p>
<p>If <span class="product-label-link" type="condition" conceptid="4105019" conceptname="Superimposed infection">superinfection</span> occurs, appropriate therapy should be instituted.</p>
<div class="Section" data-sectionCode="34076-0">
<a name="LINK_bf4d3cf9-294a-4781-bfe3-5934f9d763f7"></a><a name="section-7.1"></a><p></p>
<h2><span class="Bold"><span class="Italics">Information for Patients </span></span></h2>
<p class="First">Information for Patients. </p>
<p>Patients should be counseled that antibacterial drugs including polymyxin B for injection should only be used to treat <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infections</span>. They do not treat <span class="product-label-link" type="condition" conceptid="440029" conceptname="Viral disease">viral infections</span> (e.g., the <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">common cold</span>). When polymyxin B for injection is prescribed to treat a <span class="product-label-link" type="condition" conceptid="432545" conceptname="Bacterial infectious disease">bacterial infection</span>, patients should be told that although it is common to feel better early in the course of therapy, the medication should be taken exactly as directed. Skipping doses or not completing the full course of therapy may (1) decrease the effectiveness of the immediate treatment and (2) increase the likelihood that bacteria will develop resistance and will not be treatable by polymyxin B for injection or other antibacterial drugs in the future. </p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> is a common problem caused by antibiotics which usually ends when the antibiotic is discontinued. Sometimes after starting treatment with antibiotics, patients can develop watery and <span class="product-label-link" type="condition" conceptid="443530" conceptname="Hematochezia">bloody stools</span> (with or without <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> and <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>) even as late as two or more months after having taken the last dose of the antibiotic. If this occurs, patients should contact their physician as soon as possible. </p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="LINK_6cbf9304-b1fe-4179-be51-e372c81474d7"></a><a name="section-8"></a><p></p>
<h1><span class="Bold">ADVERSE REACTIONS </span></h1>
<p class="First"><span class="Bold">See â€œWARNINGâ€? box.</span></p>
<p><span class="Bold">Nephrotoxic reactions:</span> <span class="product-label-link" type="condition" conceptid="4168705" conceptname="Albuminuria">Albuminuria</span>, cylinduria, <span class="product-label-link" type="condition" conceptid="4261202" conceptname="Uremia">azotemia</span>, and rising blood levels without any increase in dosage.</p>
<p><span class="Bold">Neurotoxic reactions:</span> <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">Facial flushing</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span> progressing to <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, peripheral <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">paresthesias</span> (circumoral and stocking glove), <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span> due to concurrent use of curariform muscle relaxants, other neurotoxic drugs or inadvertent overdosage, and signs of <span class="product-label-link" type="condition" conceptid="441130" conceptname="Meningeal irritation">meningeal irritation</span> with intrathecal administration, e.g., <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4060220" conceptname="Stiff neck">stiff neck</span> and increased cell count and protein cerebrospinal fluid.</p>
<p><span class="Bold">Other reactions occasionally reported:</span> <span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">Drug fever</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticarial rash</span>, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> (severe) at intramuscular injection sites, and <span class="product-label-link" type="condition" conceptid="320741" conceptname="Thrombophlebitis">thrombophlebitis</span> at intravenous injection sites.</p>
<p>To report SUSPECTED ADVERSE EVENTS, contact FDA at 1-800-FDA-1088 or www.fda.gov. </p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="LINK_01046d1c-a4d4-4278-b2cc-ad3ead2981b8"></a><a name="section-9"></a><p></p>
<h1><span class="Bold">DOSAGE AND ADMINISTRATION </span></h1>
<p class="First"><span class="Bold">PARENTERAL:</span></p>
<p><span class="Underline"><span class="Bold">Intravenous.</span></span> Dissolve 500,000 polymyxin B units in 300 to 500 mL solutions for parenteral dextrose injection 5 percent for continuous drip.</p>
<p><span class="Bold">Adults and children.</span> 15,000 to 25,000 units/kg body weight/day in individuals with normal kidney function. This amount should be reduced from 15,000 units/kg downward for individuals with kidney impairment. Infusions may be given every 12 hours; however, the total daily dose must not exceed 25,000 units/kg/day.</p>
<p>Infants. Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.</p>
<p><span class="Bold"><span class="Underline">Intramuscular</span>.</span> Not recommended routinely because of severe <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> at injection sites, particularly in infants and children. Dissolve 500,000 polymyxin B units in 2 mL sterile water for injection or sodium chloride injection or procaine hydrochloride injection 1 percent.</p>
<p><span class="Bold">Adults and children.</span> 25,000 to 30,000 units/kg/day. This should be reduced in the presence of <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">renal impairment</span>. The dosage may be divided and given at either 4 or 6 hour intervals.</p>
<p><span class="Bold">Infants.</span> Infants with normal kidney function may receive up to 40,000 units/kg/day without adverse effects.</p>
<p><span class="Bold">Note:</span> Doses as high as 45,000 units/kg/day have been used in limited clinical studies in treating prematures and newborn infants for <span class="product-label-link" type="condition" conceptid="132797" conceptname="Sepsis">sepsis</span> caused by <span class="Italics">Ps</span>Â <span class="Italics">aeruginosa</span>.</p>
<p><span class="Bold"><span class="Underline">Intrathecal.</span> A treatment of choice for <span class="Italics">Ps</span>Â <span class="Italics">aeruginosa</span>Â <span class="Italics"><span class="product-label-link" type="condition" conceptid="435785" conceptname="Meningitis">meningitis</span></span>.</span> Dissolve 500,000 polymyxin B units in 10 mL sodium chloride injection USP for 50,000 units per mL dosage unit.</p>
<p><span class="Bold">Adults and children over 2 years of age.</span> Dosage is 50,000 units once daily intrathecally for 3 to 4 days, then 50,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.</p>
<p><span class="Bold">Children under 2 years of age.</span> 20,000 units once daily, intrathecally for 3 to 4 days or 25,000 units once every other day. Continue with a dose of 25,000 units once every other day for at least 2 weeks after cultures of the cerebrospinal fluid are negative and sugar content has returned to normal.</p>
<p><span class="Bold">IN THE INTEREST OF SAFETY, SOLUTIONS OF PARENTERAL USE SHOULD BE STORED UNDER REFRIGERATION, AND ANY UNUSED PORTIONS SHOULD BE DISCARDED AFTER 72 HOURS.</span></p>
<p><span class="Bold">TOPICAL:</span></p>
<p><span class="Bold"><span class="Underline">Ophthalmic</span>.</span> Dissolve 500,000 polymyxin B units in 20 to 50 mL sterile water for injection or sodium chloride injection USP for a 10,000 to 25,000 units per mL concentration.</p>
<p>For the treatment of <span class="Italics">Ps</span>Â <span class="Italics">aeruginosa</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the eye, a concentration of 0.1 percent to 0.25 percent (10,000 units to 25,000 units per mL) is administered 1 to 3 drops every hour, increasing the intervals as response indicates.</p>
<p>Subconjunctival injection of up to 100,000 units/day may be used for the treatment of <span class="Italics">Ps</span>Â <span class="Italics">aeruginosa</span> <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span> of the cornea and conjunctiva.</p>
<p><span class="Italics">Note: Avoid total systemic and ophthalmic instillation over 25,000 units/kg/day.</span></p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="LINK_ae6f36cc-a422-41f2-b8c9-ebe7f0598eb6"></a><a name="section-10"></a><p></p>
<h1><span class="Bold">HOW SUPPLIED </span></h1>
<p class="First">Polymyxin B for Injection, Each vial of Polymyxin BÂ for Injection contains polymyxin B sulfate equivalent to<br>500,000 polymyxin B units per vial. It is supplied inÂ rubber-stoppered glass vial with flip off cap, carton of 10.</p>
<p>NDC Number 39822-0171-6 Single Vial, 39822-0171-7 Ten Vial Carton</p>
<p>Storage recommendations:</p>
<p><span class="Bold">Before reconstitution</span>: Store at 20Â° to 25Â° C (68Â° to 77Â°F) (See USP controlled Room Temperature)</p>
<p><span class="Bold">Protect from light</span>. Retain in carton until time of use.</p>
<p><span class="Bold">After reconstitution:</span> Product must be stored underÂ refrigeration, between 2Â° to 8Â°C (36Â° to 46Â°F) and any<br>unused portion should be discarded after 72 hours.<br><br></p>
<p>NOVAPLUS</p>
<p>NOVAPLUS is a registered trademark of Novation, LLC.</p>
<p>Manufactured for:Â <br>X-Gen Pharmaceuticals, Inc. <br>Big Flats, NY 14814</p>
<p>Manufactured in India</p>
<p>POLY-NP-XE-PI-01</p>
<p>Revised April 2015</p>
</div>
<div class="Section" data-sectionCode="34093-5">
<a name="LINK_8f6ff234-89b3-4875-856f-72409c861f8d"></a><a name="section-11"></a><p></p>
<h1><span class="Bold">REFERENCES</span></h1>
<ol class="Arabic">
<li>Clinical and Laboratory Standards Institute (CLSI). Methods for Dilution Antimicrobial Susceptibility Test for Bacteria That Grow Aerobically; Approved Standard-8th edition. CLSI document M07-A8. CLSI, 940 West Valley Road, Suite 1400, Wayne, PA, 2009. </li>
<li>CLSI. Performance Standards for Antimicrobial Disk Susceptibility Tests; Approved Standard-10th edition. CLSI document M02-A10, 2009. </li>
<li>Clinical Laboratory and Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing: 21st Informational Supplement. CLSI document M100-S21. CLSI, 940 West Valley Rd., Suite 1400, Wayne, PA 19087, 2011. </li>
</ol>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="LINK_8a7b202d-b624-446a-9de5-5054fdec19ad"></a><a name="section-12"></a><p></p>
<h1><span class="Bold">PACKAGE LABEL.PRINCIPAL DISPLAY PANEL </span></h1>
<p class="First"><span class="Bold">NDC 39822-0171-6<br>Polymyxin B for Injection, USP<br>Sterile Â  Lyophilized<br>Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin B units.<br>Rx Only<br>500,000 units per vial<br>NOVAPLUS</span></p>
<p><img alt="poly-xe-np-vl-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=805caef0-89df-4bcf-876d-9f6b7a89c9a3&amp;name=polymyxin-b-for-injection---usp-2.jpg"><p class="MultiMediaCaptionNotCentered">poly-xe-np-vl-01</p>Â </p>
<p><span class="Bold">NDC 39822-0171-7<br>10 sterile vials<br>Polymyxin B for Injection, USP<br>Sterile Â  Lyophilized<br><span class="Bold">500,000 units per vial</span><br>FOR HOSPITAL USE ONLY, if prescribed for intramuscular, intravenous, and/or intrathecal administration.<br><span class="Bold">Each vial contains Polymyxin B Sulfate equivalent to 500,000 polymyxin B units.</span><br>Rx Only<br>NOVAPLUS</span></p>
<div class="Figure">
<img alt="poly-xe-np-cm-01" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=805caef0-89df-4bcf-876d-9f6b7a89c9a3&amp;name=polymyxin-b-for-injection---usp-3.jpg"><p class="MultiMediaCaption">poly-xe-np-cm-01</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>POLYMYXIN BÂ 		
					</strong><br><span class="contentTableReg">polymyxin b injection, powder, lyophilized, for solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:39822-0171</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">INTRAMUSCULAR, INTRAVENOUS</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">Â Â Â Â 
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>POLYMYXIN B SULFATE</strong> (POLYMYXIN B) </td>
<td class="formItem">POLYMYXIN B</td>
<td class="formItem">500000Â [USP'U]</td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:39822-0171-7</td>
<td class="formItem">10  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:39822-0171-6</td>
<td class="formItem">1  in 1 VIAL; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ANDA</td>
<td class="formItem">ANDA202766</td>
<td class="formItem">04/25/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler -Â </span>X-GEN Pharmaceuticals, Inc.
							(790169531)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Registrant -Â </span>Xellia Pharmaceuticals ApS (305814345)</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 4/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8bdc7003-2924-4cc0-bd5a-a15ea675593f</div>
<div>Set id: 805caef0-89df-4bcf-876d-9f6b7a89c9a3</div>
<div>Version: 2</div>
<div>Effective Time: 20150421</div>
</div>
</div>Â <div class="DistributorName">X-GEN Pharmaceuticals, Inc.</div></p>
</body></html>
